15 research outputs found
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
A Case of Right Subphrenic Granuloma due to the Spilled Gallstones After Laparoscopic Cholecystectomy
<Original Article> Histopathological Analysis of Intrahepatic Multiple Hepatocellular Carcinomas - Possibility of Differential Didgnosis of Their Origins by Clonal Study
<Original Article> Changes in Blood Transfusion during Liver Resection over the Past Ten Years
<Case Report> Three Indonesian Cases of Intraperitoneal Development of Metastatic Hepatocellular Carcinoma, Possibly Disseminated by Spontaneous Tumor Rupture
Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients